Long-acting medications for the hyperkinetic disorders. A systematic review and European treatment guideline
Tobias Banaschewski1, David Coghill, Paramala Santosh
1Dept. of Child & Adolescent Psychiatry/Psychotherapy, University of Goettingen, Von-Siebold-Str. 5, 37075 Goettingen, Germany. tbanasc@gwdg.de
Abstract:
A systematic review of published and unpublished data on the use of long-acting medications in ADHD and hyperkinetic disorder is reported, giving effect sizes and numbers-to-treat for extended-release stimulant preparations and atomoxetine (ATX). A panel of experts from several European countries used the review to make recommendations about the use of these drugs in practice, and conclusions are reported: (1) Long-acting preparations should be available and used; (2) They should not replace short-acting drugs (which will be the initial treatment for many children for reasons of cost and flexibility of dosing). Individual clinical choice is needed. (3) Both ATX and extended-release preparations of stimulants should be available. The choice will depend upon the circumstances, and detailed recommendations are made.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drug Therapy
Antianxiety Medications
Psychosis: Goals of Pharmacotherapy
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
Alzheimer's Disease: Treatment
Mania and Antimanic Drugs: Overview

